162 related articles for article (PubMed ID: 38442454)
1. Gut microbiota and metabolites as predictors of biologics response in inflammatory bowel disease: A comprehensive systematic review.
Wang C; Gu Y; Chu Q; Wang X; Ding Y; Qin X; Liu T; Wang S; Liu X; Wang B; Cao H
Microbiol Res; 2024 May; 282():127660. PubMed ID: 38442454
[TBL] [Abstract][Full Text] [Related]
2. Metabolic Functions of Gut Microbes Associate With Efficacy of Tumor Necrosis Factor Antagonists in Patients With Inflammatory Bowel Diseases.
Aden K; Rehman A; Waschina S; Pan WH; Walker A; Lucio M; Nunez AM; Bharti R; Zimmerman J; Bethge J; Schulte B; Schulte D; Franke A; Nikolaus S; Schroeder JO; Vandeputte D; Raes J; Szymczak S; Waetzig GH; Zeuner R; Schmitt-Kopplin P; Kaleta C; Schreiber S; Rosenstiel P
Gastroenterology; 2019 Nov; 157(5):1279-1292.e11. PubMed ID: 31326413
[TBL] [Abstract][Full Text] [Related]
3. Predictors of Primary Response to Biologic Treatment [Anti-TNF, Vedolizumab, and Ustekinumab] in Patients With Inflammatory Bowel Disease: From Basic Science to Clinical Practice.
Gisbert JP; Chaparro M
J Crohns Colitis; 2020 Jun; 14(5):694-709. PubMed ID: 31777929
[TBL] [Abstract][Full Text] [Related]
4. Fecal Microbiome Changes and Specific Anti-Bacterial Response in Patients with IBD during Anti-TNF Therapy.
Schierova D; Roubalova R; Kolar M; Stehlikova Z; Rob F; Jackova Z; Coufal S; Thon T; Mihula M; Modrak M; Kverka M; Bajer L; Kostovcikova K; Drastich P; Hercogova J; Novakova M; Vasatko M; Lukas M; Tlaskalova-Hogenova H; Jiraskova Zakostelska Z
Cells; 2021 Nov; 10(11):. PubMed ID: 34831411
[TBL] [Abstract][Full Text] [Related]
5. The gut microbiota and metabolome are associated with diminished COVID-19 vaccine-induced antibody responses in immunosuppressed inflammatory bowel disease patients.
Alexander JL; Mullish BH; Danckert NP; Liu Z; Olbei ML; Saifuddin A; Torkizadeh M; Ibraheim H; Blanco JM; Roberts LA; Bewshea CM; Nice R; Lin S; Prabhudev H; Sands C; Horneffer-van der Sluis V; Lewis M; Sebastian S; Lees CW; Teare JP; Hart A; Goodhand JR; Kennedy NA; Korcsmaros T; Marchesi JR; Ahmad T; Powell N
EBioMedicine; 2023 Feb; 88():104430. PubMed ID: 36634565
[TBL] [Abstract][Full Text] [Related]
6. Gut microbiome-associated predictors as biomarkers of response to advanced therapies in inflammatory bowel disease: a systematic review.
Meade S; Liu Chen Kiow J; Massaro C; Kaur G; Squirell E; Bressler B; Lunken G
Gut Microbes; 2023 Dec; 15(2):2287073. PubMed ID: 38044504
[TBL] [Abstract][Full Text] [Related]
7. Attributes of intestinal microbiota composition and their correlation with clinical primary non-response to anti-TNF-α agents in inflammatory bowel disease patients.
Alatawi H; Mosli M; Saadah OI; Annese V; Al-Hindi R; Alatawy M; Al-Amrah H; Alshehri D; Bahieldin A; Edris S
Bosn J Basic Med Sci; 2022 Jun; 22(3):412-426. PubMed ID: 34761733
[TBL] [Abstract][Full Text] [Related]
8. Systematic review: the association between the gut microbiota and medical therapies in inflammatory bowel disease.
Radhakrishnan ST; Alexander JL; Mullish BH; Gallagher KI; Powell N; Hicks LC; Hart AL; Li JV; Marchesi JR; Williams HRT
Aliment Pharmacol Ther; 2022 Jan; 55(1):26-48. PubMed ID: 34751954
[TBL] [Abstract][Full Text] [Related]
9. Fecal Microbiota Signatures Are Associated with Response to Ustekinumab Therapy among Crohn's Disease Patients.
Doherty MK; Ding T; Koumpouras C; Telesco SE; Monast C; Das A; Brodmerkel C; Schloss PD
mBio; 2018 Mar; 9(2):. PubMed ID: 29535202
[TBL] [Abstract][Full Text] [Related]
10. The oral-gut axis: Salivary and fecal microbiome dysbiosis in patients with inflammatory bowel disease.
Abdelbary MMH; Hatting M; Bott A; Dahlhausen A; Keller D; Trautwein C; Conrads G
Front Cell Infect Microbiol; 2022; 12():1010853. PubMed ID: 36275026
[TBL] [Abstract][Full Text] [Related]
11. Gut microbiota in mucosa and feces of newly diagnosed, treatment-naïve adult inflammatory bowel disease and irritable bowel syndrome patients.
Čipčić Paljetak H; Barešić A; Panek M; Perić M; Matijašić M; Lojkić I; Barišić A; Vranešić Bender D; Ljubas Kelečić D; Brinar M; Kalauz M; Miličević M; Grgić D; Turk N; Karas I; Čuković-Čavka S; Krznarić Ž; Verbanac D
Gut Microbes; 2022; 14(1):2083419. PubMed ID: 35695669
[TBL] [Abstract][Full Text] [Related]
12. Dysbiosis in the Gut Microbiota in Patients with Inflammatory Bowel Disease during Remission.
Pisani A; Rausch P; Bang C; Ellul S; Tabone T; Marantidis Cordina C; Zahra G; Franke A; Ellul P
Microbiol Spectr; 2022 Jun; 10(3):e0061622. PubMed ID: 35532243
[TBL] [Abstract][Full Text] [Related]
13. Gut Microbial Metabolite Butyrate and Its Therapeutic Role in Inflammatory Bowel Disease: A Literature Review.
Recharla N; Geesala R; Shi XZ
Nutrients; 2023 May; 15(10):. PubMed ID: 37242159
[No Abstract] [Full Text] [Related]
14. Prior Immunogenicity to Anti-TNF Biologics Is Not Associated with Increased Anti-drug Antibodies to Vedolizumab or Ustekinumab.
Costable NJ; Borman ZA; Ji J; Dubinsky MC; Ungaro RC
Dig Dis Sci; 2022 Jun; 67(6):2480-2484. PubMed ID: 34021427
[TBL] [Abstract][Full Text] [Related]
15. Appropriate Therapeutic Drug Monitoring of Biologic Agents for Patients With Inflammatory Bowel Diseases.
Papamichael K; Cheifetz AS; Melmed GY; Irving PM; Vande Casteele N; Kozuch PL; Raffals LE; Baidoo L; Bressler B; Devlin SM; Jones J; Kaplan GG; Sparrow MP; Velayos FS; Ullman T; Siegel CA
Clin Gastroenterol Hepatol; 2019 Aug; 17(9):1655-1668.e3. PubMed ID: 30928454
[TBL] [Abstract][Full Text] [Related]
16. Pharmacodynamic mechanisms behind a refractory state in inflammatory bowel disease.
Goll R; Moe ØK; Johnsen KM; Meyer R; Friestad J; Gundersen MD; Kileng H; Johnsen K; Florholmen JR
BMC Gastroenterol; 2022 Nov; 22(1):464. PubMed ID: 36384462
[TBL] [Abstract][Full Text] [Related]
17. Interplay of host genetics and gut microbiota underlying the onset and clinical presentation of inflammatory bowel disease.
Imhann F; Vich Vila A; Bonder MJ; Fu J; Gevers D; Visschedijk MC; Spekhorst LM; Alberts R; Franke L; van Dullemen HM; Ter Steege RWF; Huttenhower C; Dijkstra G; Xavier RJ; Festen EAM; Wijmenga C; Zhernakova A; Weersma RK
Gut; 2018 Jan; 67(1):108-119. PubMed ID: 27802154
[TBL] [Abstract][Full Text] [Related]
18. Human Gut Microbiome Transplantation in Ileitis Prone Mice: A Tool for the Functional Characterization of the Microbiota in Inflammatory Bowel Disease Patients.
Basson AR; Gomez-Nguyen A; Menghini P; Buttó LF; Di Martino L; Aladyshkina N; Osme A; LaSalla A; Fischer D; Ezeji JC; Erkkila HL; Brennan CJ; Lam M; Rodriguez-Palacios A; Cominelli F
Inflamm Bowel Dis; 2020 Feb; 26(3):347-359. PubMed ID: 31750921
[TBL] [Abstract][Full Text] [Related]
19. Fecal Microbiota and Metabolome in a Mouse Model of Spontaneous Chronic Colitis: Relevance to Human Inflammatory Bowel Disease.
Robinson AM; Gondalia SV; Karpe AV; Eri R; Beale DJ; Morrison PD; Palombo EA; Nurgali K
Inflamm Bowel Dis; 2016 Dec; 22(12):2767-2787. PubMed ID: 27824648
[TBL] [Abstract][Full Text] [Related]
20. Review article: how the intestinal microbiota may reflect disease activity and influence therapeutic outcome in inflammatory bowel disease.
Caenepeel C; Sadat Seyed Tabib N; Vieira-Silva S; Vermeire S
Aliment Pharmacol Ther; 2020 Nov; 52(9):1453-1468. PubMed ID: 32969507
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
